Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
12112studies shown
Showing 5,317-5,328 of 12,112
Other study type icon
CompletedNCT00376220

A Placebo Controlled study of Riluzole in Depression in bipolarity

This study is completed in the United States. It is testing Double-Blind Placebo Controlled Trial of Riluzole for depression in bipolarity.

In Baltimore
Bipolarity, DepressionOtherFrom 18 Years to 75 Years
Countries
United States
Sponsor
Johns Hopkins University
Condition
Bipolarity, Depression
Drug study icon
CompletedEUCTR 2018-002782-19

CARIPRAZINE for depression

This study is completed in the United Kingdom, in Germany, in Hungary, .... It is testing CARIPRAZINE for depression.

In Germany
DepressionOther
Countries
United Kingdom, Germany, Hungary, ...
Sponsor
Allergan Ltd.
Condition
Depression
Other study type icon
OngoingEUCTR 2017-002227-13

Pimavanserin for Schizophrenia

This study is ongoing in France, in the United Kingdom, in Czechia, .... It is testing pimavanserin for Schizophrenia.

In United Kingdom
SchizophreniaOther
Countries
France, United Kingdom, Czechia, ...
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2020-000341-14

Seltorexant 20 mg for Depression

This study is completed in the United Kingdom, in Belgium, in Czechia, .... It is testing Seltorexant 20 mg for Depression.

In Czech Republic
DepressionOther
Countries
United Kingdom, Belgium, Czechia, ...
Sponsor
Janssen-Cilag International NV
Condition
Depression
Other study type icon
TerminatedEUCTR 2010-020493-42

Vortioxetine for depression

This study was terminated in Bulgaria, in Poland, in Latvia, .... It is testing vortioxetine for depression.

In Bulgaria
DepressionOther
Countries
Bulgaria, Poland, Latvia, ...
Sponsor
H. Lundbeck A/S
Condition
Depression
Drug study icon
CompletedNCT01094249

Valproic Acid and Paliperidone Extended-Release (ER) for schizophrenia

This study is completed in the United States. It is testing Valproic Acid and Paliperidone Extended-Release (ER) for schizophrenia.

Multiple locations, including Kissimmee
Bipolarity, SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Bipolarity, Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.